Meridian Bioscience Initiates Guidance for FY 2014, Reaffirms FY 2013 Guidance | GenomeWeb

NEW YORK (GenomeWeb News) – Meridian Bioscience today initiated sales and earnings guidance for its Fiscal Year 2014, while it reiterated prior guidance for full-year fiscal 2013.

For FY 2014, the Cincinnati-based company said that net sales are anticipated to be in the range of $203 million and $208 million. It guided to EPS of between $.98 and $1.03, saying net earnings are anticipated to increase between 10 and 15 percent compared to fiscal 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.